Aiforia Technologies Oyj

Aiforia is a Finnish company specializing in developing AI-powered image analysis software for medical research and diagnostics. The company aims to enhance healthcare outcomes by enabling precise diagnoses and personalized patient care. Aiforia's solutions cater to the growing demand for digital pathology, driven by an aging population and the increasing prevalence of diseases like cancer. The company's offerings streamline medical image analysis across various fields, including oncology and neuroscience, through its deep-learning software solutions and expert services.

73

3.09

3.02

— Aiforia Technologies Oyj
%
AI Image Analysis Software40% AI-powered software for medical research and diagnostics.
SaaS Solutions30% Subscription-based software for pathology diagnostics.
Custom Expert Services15% Tailored services for researchers and pathologists.
Clinical Solutions15% AI solutions to enhance hospital efficiency and diagnostics.

Aiforia's customer base includes researchers, pathologists, and hospitals seeking to enhance diagnostic accuracy and...

  • Researchersprimary

    Use AI for advanced medical studies and biomarker discovery.

  • Pathologistsprimary

    Seek efficient diagnostic tools to streamline workflows.

  • Hospitalssecondary

    Aim to improve diagnostic accuracy and patient outcomes.

  • Laboratoriessecondary

    Undergoing digital transformation with AI solutions.

Aiforia is headquartered in Finland and has a significant presence in the United States, where a large portion of its...

  • Headquartered in Finland with significant US market presence
  • Subsidiary in France to strengthen European operations
  • Key markets include North America and Europe
  • Revenue generation primarily from US and European markets
  • International presence helps mitigate currency risks

Aiforia's strategic priorities focus on expanding its product offerings and achieving profitability by 2027...

01
Expand product offeringsmedium-term

To cover 80% of diagnostic workflows

02
Achieve profitabilitylong-term

To ensure sustainable growth

03
Increase revenuemedium-term

To reach over €100 million

Aiforia faces several risks, including financial instability due to its current unprofitable status and reliance on...

critical

Financial instability

Current unprofitable status and funding reliance

Materiality
high
high

Currency fluctuations

Significant revenue from US market

Materiality
medium
high

Product development success

Critical for future growth

Materiality
high
medium

Regulatory changes

Evolving medical device regulations

Materiality
medium
Revenue recognition timing
high
Capitalization of development costs
medium
Currency fluctuations
medium

: 11/08/2026